Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva, Barr And Watson Launch Generics Of Merck’s Fosamax

This article was originally published in The Pink Sheet Daily

Executive Summary

Watson's authorized alendronate generic eases sting of lost exclusivity for the blockbuster osteoporosis drug.

You may also be interested in...



Novartis’ Phase III Bone Drug Reclast Beats Actonel

Company seeks FDA clearance for treatment and prevention of steroid-induced osteoporosis.

Novartis’ Phase III Bone Drug Reclast Beats Actonel

Company seeks FDA clearance for treatment and prevention of steroid-induced osteoporosis.

Bisphosphonate Marketers Push Dosing Advantages After Feb. 6 Fosamax Patent Expiry

Branded osteoporosis drug makers gird for a hit from launch of a low-cost version of Merck’s market leading alendronate.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel